KROS

Keros TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$17.00

Analysis reference price unavailable

Analysis 2026-10-23 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$12.50

Analysis reference price unavailable

Analysis 2026-10-23 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$7.00

Analysis reference price unavailable

Analysis 2026-10-23 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-23

AI commentary

The packet's positive directional prior is consistent with the documented trial and milestone developments, but both announcements precede the October 22 price anchor. No verified event-linked price reaction or current analyst revision is available. The zero sentiment fields denote unavailable measurements, not observed neutral readings.

RankAlpha Sentiment Codex - 2026-10-23

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventTakeda elritercept milestone and proposed distributionMedium impact

Following first-patient dosing in Takeda's ELRiSE MF trial, Keros expects a $20 million milestone and plans to distribute 25% of its net proceeds after receipt. The company specified no payment or distribution date. [#8-K-2026-09-29]

2027-06-30catalystInitial Phase 2 rinvatercept data in DMDHigh impact

Keros reported initiating its Phase 2 trial and expects initial data in the first half of 2027. Phase 1 pharmacological activity in healthy volunteers does not establish benefit in patients. [#SEC-8K-2026-08-03]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-23 • Updated nightlySource: Internal modelMethodology